Loading organizations...
§ Private Profile · Or Akiva, Hefa, Israel
Developing proprietary hydrogels for tissue regeneration.
Regentis Biomaterials has raised $25.0M across 2 funding rounds.
Regentis Biomaterials has raised $25.0M in total across 2 funding rounds.
Regentis Biomaterials has raised $25.0M across 2 funding rounds. Most recently, it raised $15.0M Series D in February 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 11, 2016 | $15M Series D | Haisco Pharmaceutical Group | Generali, Medica Venture Partners, SCP Vitalife Partners, Technion Innovation Opportunities Fund, Technion Research And Development Foundation | Announced |
| May 14, 2012 | $10M Series C | — | Crossroad Fund, Medica Venture Partners, Royal DSM, SCP Vitalife Partners, Technion | Announced |
Regentis Biomaterials has raised $25.0M in total across 2 funding rounds.
Regentis Biomaterials's investors include Haisco Pharmaceutical Group, Generali, Medica Venture Partners, SCP Vitalife Partners, Technion Innovation Opportunities Fund, Technion Research and Development Foundation, Crossroad Fund, Royal DSM, Technion.